Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants

In November 2010, the iPrEx study reported that pre-exposure prophylaxis (PrEP) with daily tenofovir disoproxil fumarate/emtricitabine reduced HIV infections by 44% among men who have sex with men and subsequent trials corroborated efficacy among heterosexual men and women. During regularly schedule...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Fuchs, Jonathan D., Sobieszczyk, Magdalena E., Madenwald, Tamra, Grove, Doug, Karuna, Shelly T., Andrasik, Michele, Sherwat, Adam, Broder, Gail, Mayer, Kenneth, Koblin, Beryl, Hammer, Scott
Format: Artigo
Langue:Inglês
Publié: 2013
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3714219/
https://ncbi.nlm.nih.gov/pubmed/23614998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e318296df94
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires